The Evolving Landscape of Wellness Resorts: How GLP-1 Medications Are Reshaping the Industry
In the wake of the COVID-19 pandemic, wellness resorts experienced a surge in popularity as people sought refuge from the stresses of lockdowns. However, as the world gradually returned to normalcy, these retreats now face a new challenge: the rise of GLP-1 medications, which are transforming the weight-loss landscape and altering the dynamics of the wellness industry.
A Pandemic Boom
During the height of the pandemic in 2021, wellness resorts like Movara in Ivins, Utah, thrived. With a focus on fitness and weight loss, Movara was fully booked for 18 consecutive weeks, reflecting a broader trend among similar retreats. Hilton Head Health in South Carolina and Skyterra Wellness Retreat in North Carolina also reported long waitlists, as individuals sought to improve their health during a time of uncertainty.
However, as vaccination rates increased and travel restrictions eased, many people began to prioritize leisure and indulgence over wellness. Destinations like Italy became popular for their culinary delights, while international travelers hesitated to visit the U.S. This shift in priorities coincided with the emergence of GLP-1 medications, such as Ozempic and Wegovy, which have gained traction for their off-label use in weight loss.
The GLP-1 Disruption
GLP-1 medications, originally developed for Type 2 diabetes management, have become a game-changer in the weight-loss arena. These drugs promise significant and sustained weight loss without the need for traditional methods like calorie counting or rigorous exercise. With costs around $500 per month, depending on insurance, they offer a seemingly effortless solution to weight management.
As a result, wellness resorts are grappling with a decline in guest numbers. The global wellness market, valued at approximately $6.3 trillion, is feeling the impact of this pharmacological shift. To survive, many resorts are rethinking their offerings and integrating GLP-1 medications into their programs.
A Shift in Perspective
Michelle Kelsch, co-founder of Movara, initially dismissed GLP-1s as a passing trend, much like previous diet fads. For over three decades, she has advocated for a philosophy centered on exercise, discipline, and calorie management. However, as the popularity of GLP-1s surged, Kelsch began to reconsider her stance. “This is the first thing I’ve seen in 25 years that aligns with what I’ve always taught,” she remarked, acknowledging the potential of these medications to complement traditional wellness approaches.
Adapting to Change
At Hilton Head Health, the resort experienced a dip in new guest arrivals in 2023, which program director David Chesworth attributes, at least in part, to the rise of GLP-1 medications. Guests who might have previously sought out weight-loss programs are now opting to try these drugs first. In response, the resort has introduced the H3 Experience, a program designed to help guests evaluate the pros and cons of GLP-1s while maintaining a holistic approach to health.
Similarly, The Ranch in Malibu has seen a shift in its clientele, with an increasing number of menopausal women and GLP-1 users. The resort continues to emphasize its traditional offerings, such as vegan meals and rigorous fitness routines, but now also provides support for guests using GLP-1 medications. Programs tailored for these individuals can cost upwards of $12,400 for six nights, reflecting the growing demand for specialized services.
Mountain Trek Health Reset Retreat in British Columbia has also adapted its approach, focusing on the dietary needs of GLP-1 users. Owner Alex Timmons emphasizes the importance of balancing calories and macronutrients to ensure guests do not experience negative side effects like dehydration or muscle loss.
Skyterra, known for its personalized retreats, has partnered with local medical professionals to offer consultations for guests interested in GLP-1 medications. Their four-week retreats, which include support for maintaining muscle mass while on these drugs, are priced at $18,480.
Historical Context and Industry Evolution
The wellness industry has a history of adapting to changing trends, from the aerobics boom of the 1980s to the resurgence of yoga in the early 2000s. Craig Oliver, founder of Spas of America, notes that spas have consistently had to innovate to meet evolving consumer demands. The rise of GLP-1 medications represents another significant shift that resorts must navigate.
A recent survey by KFF revealed that approximately 1 in 8 U.S. adults have used a GLP-1 drug, while 1 in 6 practice yoga. The use of GLP-1s is projected to increase by over 73% by 2025, potentially affecting 1 in 5 adult Americans. This growth is partly fueled by increased accessibility, as pharmaceutical companies like Novo Nordisk have reduced prices for these medications.
The Future of Wellness Resorts
As the wellness industry grapples with the implications of GLP-1 medications, experts predict a need for a new paradigm that integrates medicine, wellness, and technology. Susie Ellis, chair and CEO of the Global Wellness Institute, emphasizes that spas must rethink their offerings to cater to the unique needs of GLP-1 users.
Movara’s Kelsch has embraced this shift, even trying a GLP-1 medication herself. After experiencing positive results, she has encouraged her family to consider the drug as well. “GLP-1s may honestly be as essential for people struggling with extra weight as corrective lenses for people with bad eyesight,” she stated, highlighting the potential of these medications to transform lives.
Conclusion
The rise of GLP-1 medications is reshaping the landscape of wellness resorts, forcing them to adapt to a new reality where traditional weight-loss methods may no longer suffice. As these retreats evolve to incorporate pharmacological solutions into their programs, they face both challenges and opportunities. The future of wellness may well depend on the ability of these resorts to blend the best of medicine and holistic health, ensuring they remain relevant in an ever-changing market.
